Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:2/16/2010

l also receive, on a blinded basis, either intravenous placebo or intravenous REOLYSIN. All dosing takes place in the first five days of each cycle with all patients receiving standard intravenous doses of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN at a dose of 3x1010 TCID50. Patients may continue to receive the trial combination therapy for up to eight, 21-day cycles and, thereafter, blinded placebo or blinded REOLYSIN until the patient has progressive disease or meets other criteria for removal from the trial. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium.

The primary endpoint for the trial is overall survival (OS); secondary endpoints include progression free survival (PFS), objective response rate (complete response (CR) + partial response (PR)) and duration of response, and safety and tolerability of REOLYSIN when administered in combination with paclitaxel and carboplatin. The first stage of the trial is designed to enroll 80 patients. The second stage is adaptive, and is designed to enroll between 100 and 400 patients with the most probable statistical enrolment being 195 patients in this stage. This adaptive trial design allows frequent data evaluation to determine if the probability of reaching a statistically significant endpoint has been achieved.

The decision to pursue a Phase 3 trial in head and neck cancers was predicated on positive results seen in the Company's U.K. Phase 1 and Phase 2 combination REOLYSIN and paclitaxel/carboplatin clinical trials, as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Updated results from the U.K. Phase 1/2 trial reported in November 2009 demonstrated an overall response rate (PR and CR) of 42% and a total clinical ben
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Research and Markets ... Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism (SNP) genotyping ... SNPs in the genome of various species. SNPs are ... and analysis technology can analyze thousands of SNPs and ...
(Date:8/1/2014)... ON (PRWEB) August 01, 2014 ... has led to a better understanding embryonic development. ... and reorganize into structurally and functionally distinct tissues ... physical defects. Prof. Todd McDevitt, Melissa Kinney, ... biophysical signals interact with biochemical cues to control ...
(Date:7/31/2014)... reason people over 60 are not donor candidates for ... with time, making the elderly prone to life-threatening infection ... team now has discovered a reason why. , "We ... of blood-forming cells to maintain blood production over time ... that could be restored for rejuvenation therapies," said Emmanuelle ...
(Date:7/31/2014)... SPRINGS, Colo. , July 31, 2014 /PRNewswire-USNewswire/ ... Grant awardee today with $25,000 to fund a ... Foundation,s inception in 2011, the gift was presented ... th Annual Meeting in Colorado ... who specialize in neurointerventional approaches to neurovascular conditions, ...
Breaking Biology Technology:Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Study Links Biomechanics and Gene Expression in Stem Cells 2Key to aging immune system is discovered 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... Seamless Performance Between GeneChip Scanner 3000 and the ... , ... Instrument System is the most advanced microarray analysis platform available and ... processes have enabled Affymetrix to produce expression probe arrays with greater consistency ...
... , Gang Li a , Savvas Damaskinos a ... a Biomedical Photometrics Inc., A12-550 Parkside ... b Dept. of Biology, Wilfrid Laurier University, 75 University Ave. ... , ABSTRACT , ...
... , L.Pereira, 1 M.Woodruff, 1 P.Deland, 2 ... , ... CA,USA , 3 Astra Zeneca R&D, Charnwood,UK , ... performance of various diode array detectors in the analysis of trace related substances of a ...
Cached Biology Technology:The New Affymetrix GeneChip Scanner 3000 2The New Affymetrix GeneChip Scanner 3000 3The New Affymetrix GeneChip Scanner 3000 4The New Affymetrix GeneChip Scanner 3000 5The New Affymetrix GeneChip Scanner 3000 6The New Affymetrix GeneChip Scanner 3000 7The New Affymetrix GeneChip Scanner 3000 8The New Affymetrix GeneChip Scanner 3000 9The New Affymetrix GeneChip Scanner 3000 10The New Affymetrix GeneChip Scanner 3000 11The New Affymetrix GeneChip Scanner 3000 12The New Affymetrix GeneChip Scanner 3000 13The New Affymetrix GeneChip Scanner 3000 14The New Affymetrix GeneChip Scanner 3000 15A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 2A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 3A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 4A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 5A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 6A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 7A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 8A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 9A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 10A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 11A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 12A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 13A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 14A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 15A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 16A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 17A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 18A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 19A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 20A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 21A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 22
(Date:7/31/2014)... Census Bureau, Latinos are the largest minority group in ... Approximately one-third of Latinos are obese and are 1.2 ... Whites. , NYU College of Nursing student researcher ... identify the factors that contribute to this problem by ... on food patterns in Latina women recently published in ...
(Date:7/31/2014)... follow-up study (HPV-023; NCT00518336) shows the sustained ... papilloma virus (HPV) vaccine Cervarix. Women vaccinated ... for more than nine years, and vaccine ... This is the longest follow-up report for ... for the full paper. , ...
(Date:7/31/2014)... from Spain, France, and the U.S. has discovered ... oldest definitive member of the tribe Omaliini that ... and description were made possible through the use ... which allows the detailed study of otherwise invisible ... described in the journal Annals of the ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... Electrical noise, like the crackle heard on AM radio when ... electronic devices. But within cells, a similar kind of biochemical ... another, according to a new study led by a UT ... professor of pharmacology, said his research and that of his ...
... asparaginase fails to help cure some children with acute ... in the bone marrow counteract the effect of that ... Hospital. , The researchers showed that mesenchymal cells ... leukemic cells by releasing large amounts of asparagine, an ...
... understanding of how tool use has evolved among primates, ... some conditions, are capable of habitually fashioning and using ... Jill Pruetz of Iowa State University and Paco Bertolani ... the journal Current Biology on February 22nd. , Chimpanzees ...
Cached Biology News:Cells use 'noise' to make cell-fate decisions 2Cells use 'noise' to make cell-fate decisions 3Leukemic cells find safe haven in bone marrow 2Leukemic cells find safe haven in bone marrow 3Chimpanzees found to use tools to hunt mammalian prey 2
... The Light Diagnostics Universal Amplicon ... for use in the qualitative ... generated by in vitro ... use only; not to be ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
... complete ready-to-use reagents for the isolation of ... formulated for the isolation of genomic DNA ... formulated for the isolation of genomic DNA ... Reagents can be used for restriction endonuclease ...
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Biology Products: